A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Lakewood-Amedex Biotherapeutics's Debt-to-EBITDA or its related term are showing as below:
LABT'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.52 Med: -0.07 Max: -0.06
Current: -0.52
During the past 3 years, the highest Debt-to-EBITDA Ratio of Lakewood-Amedex Biotherapeutics was -0.06. The lowest was -0.52. And the median was -0.07.
LABT's Debt-to-EBITDA is ranked worse than 100% of 292
companies
in the Biotechnology industry
Industry Median: 1.215
vs LABT: -0.52
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Lakewood-Amedex Biotherapeutics Debt-to-EBITDA Related Terms
Lakewood-Amedex Biotherapeutics Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LABT vs CURX, PBM, NCNA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Lakewood-Amedex Biotherapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lakewood-Amedex Biotherapeutics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lakewood-Amedex Biotherapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lakewood-Amedex Biotherapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Lakewood-Amedex Biotherapeutics (LABT) has a Debt-to-EBITDA of -0.51 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Lakewood-Amedex Biotherapeutics. According to the industry distribution chart, Lakewood-Amedex Biotherapeutics ranks #999999 out of 292 companies in the Biotechnology industry.
Is Lakewood-Amedex Biotherapeutics' Debt-to-EBITDA too high?
Lakewood-Amedex Biotherapeutics' current Debt-to-EBITDA is -0.51. Based on the distribution chart, Lakewood-Amedex Biotherapeutics ranks #999999 out of 292 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lakewood-Amedex Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Lakewood-Amedex Biotherapeutics' Debt-to-EBITDA compare to CURX and PBM?
According to the Biotechnology industry distribution chart, Lakewood-Amedex Biotherapeutics ranks #999999 out of 292 companies for Debt-to-EBITDA. This places Lakewood-Amedex Biotherapeutics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.22, based on 292 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Lakewood-Amedex Biotherapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lakewood-Amedex Biotherapeutics's current Debt-to-EBITDA is -0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakewood-Amedex Biotherapeutics stock overvalued right now?
Lakewood-Amedex Biotherapeutics (LABT) has a current Debt-to-EBITDA of -0.51. The current Debt-to-EBITDA is -0.51. Lakewood-Amedex Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Lakewood-Amedex Biotherapeutics (LABT), the current Debt-to-EBITDA is -0.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lakewood-Amedex Biotherapeutics Business Description
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
8GF Score
Get the complete analysis for LABT
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABT has been successfully added to your 